RBC Capital Markets downgrades British American Tobacco (BATS) to ‘Sell' with GBX 3,600 target
British American Tobacco (BATS) shares are trading down 3.5% on 2 June 2026, following a "Sell" rating issued by RBC Capital Markets. The downgrade, which set a price target of GBX 3,600, has overshadowed the company's reaffirmation of its full-year 2026 guidance. British American Tobacco is currently trading at 4,422p, down from its previous close of 4,581p.
RBC's negative analyst action appears to be the primary driver of the decline, despite British American Tobacco's upward revision of its new-category revenue growth expectations to mid-teens. This revision was attributed to robust demand for vapes and nicotine pouches. BofA Securities also reiterated a "Buy" rating with a GBP53.00 price target, yet this did not mitigate the market's reaction to the "Sell" call.
Concerns persist regarding a slightly steeper global cigarette volume decline and foreign exchange headwinds. Weaker-than-expected performance in the Asia-Pacific, Middle East, and Africa region further contributes to investor caution. The current movement extends a recent decline, with shares having closed at £4,581.00 on Monday, 1 June 2026.
Why an Analyst's Downgrade Can Shift a Stock's Trajectory
British American Tobacco is a major global player in the nicotine market, primarily known for manufacturing and selling traditional cigarettes under various well-known brands. Beyond conventional tobacco, the company has increasingly diversified into "new categories", including vapes and nicotine pouches, which are designed to offer alternatives to smoking. Their customers are adult consumers worldwide who purchase these products through various retail channels, generating revenue from sales across a wide geographic footprint.
Today's movement for British American Tobacco shares stems directly from a "Sell" rating issued by RBC Capital Markets. An analyst's rating acts as a professional opinion on a company's future stock performance, often based on a detailed financial model and market outlook. When a prominent firm like RBC downgrades a stock to "Sell" and sets a lower price target, it signals to the market that their expert view on the company's valuation has worsened. This negative assessment, which included a price target of GBX 3,600, overshadowed the company's own positive news, such as reaffirming its full-year guidance and revising upwards its new-category revenue growth expectations for products like vapes. Even a "Buy" rating from BofA Securities could not counteract the weight of RBC's negative call.
This analyst action directly correlates with British American Tobacco's shares trading down by exactly 3.5% today, currently at 4,422p, a drop from yesterday's close of 4,581p.
Consider a film director whose upcoming movie has just received a scathing review from a highly respected critic. Even if the studio has been promoting strong early audience reactions and robust pre-sales, that single, influential negative review can significantly temper public enthusiasm and impact box office predictions. Similarly, an analyst downgrade from a major firm can reshape investor sentiment, overriding otherwise positive company announcements.
British American Tobacco
British American Tobacco p.l.c. (BATS) operates within the consumer defensive sector, specialising in tobacco and nicotine products. Its diverse portfolio encompasses traditional combustible cigarettes, modern oral nicotine offerings like snus and moist snuff, and next-generation products such as vapour and heated tobacco. The company markets these products globally under well-known brands including Kent, Dunhill, Lucky Strike, Pall Mall, Rothmans, and Camel, distributing them through various retail channels. Established in 1902, British American Tobacco maintains its headquarters in London, United Kingdom.